by Kande Betu Kumeso V, Perdrieu C, Menétrey C, Ilunga Wa Kyhi M, Ngolo Tete T, Camara M, Tampwo J, Kavunga P, Layba Camara M, Kourouma A, Kuziena Mindele W, Akwaso Masa F, Mahenzi H, Makaya J, Mayala Malu T, Mandula G, Mpoyi Muamba Nzambi D, Luwawu Ntoya S, Reymondier A, Mutombo Kalonji W, Scherrer B, Valverde Mordt O. The Lancet Global Health 2025, 13(5):e900-e909. doi: 10.1016/S2214-109X(24)00526-6
Summary: Fexinidazole a is safe, effective, and easy to administer treatment for most adult and paediatric patients with gambiense human African trypanosomiasis. The authors of this manuscript investigated the effectiveness and safety of fexinidazole in a wider population and explored whether treatment was feasible outside of hospital. 174 patients were either treated in hospital (including 24 women treated before/during pregnancy or during breastfeeding) or at home with a caregiver’s support. At 18 months, treatment was effective in 93.1% of patients (95%CI 88.3-96.4), which is similar to previous reports, and no new safety signals were identified. All 38 outpatients completed treatment, although three did so at hospital, indicating that home treatment may be feasible in selected patients with appropriate support.
The post Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: A phase IIIb, prospective, open-label, non-randomised, cohort study first appeared on DNDi.